Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on mortality rates (all-cause mortality) is the attribute that most influences primary care physicians' (PCPs) prescribing decisions in the treatment of hypertension. Clinical data and expert opinion shows that Novartis's Tekturna HCT, Novartis's Exforge and Sanofi-Aventis's ilepatril all have advantages in this attribute over sales- leading amlodipine.

The new report entitled Hypertension: Many Treatment Options, but None Stands Out in the Efficacy Measures Most Important to PCPs finds that of the emerging therapies in this market, fixed-dose combinations and ilepatril will be most efficacious at lowering blood pressure. Surveyed PCPs indicate that they would prescribe each of Tekturna HCT, aliskiren/valsartan and ilepatril to 10 percent of their patients with hypertension.

The report also finds that, through 2016, there are no therapies in development that will displace Exforge as the clinical gold standard treatment for hypertension. Exforge has achieved its current gold standard status owing to its enhanced efficacy and safety when compared to other hypertension treatments.

"Experts we interviewed indicated that fixed-dose combinations, including Exforge, are the most effective currently available agents at lowering both systolic and diastolic blood pressure," said Jeremy Goldman, M.D., analyst at Decision Resources. "As a result of its effect on reducing blood pressure, Exforge is also likely to reduce complications of hypertension, such as myocardial infarction and stroke, to a greater degree than other currently marketed products."

About the Report

Hypertension: Many Treatment Options, but None Stands Out in the Efficacy Measures Most Important to PCPs is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

'Cost Estimator' Helps To Fill the Information Gap for North Carolina Health Plan Members

View Now